Resolution of the Expert сouncil on сurrent issues in the treatment of patients with hemophilia A with clotting factor VIII with prolonged half-life (INN – Efmoroctocog alfa)

1. Instructions for the medical use of the drug Eloctate (Efmoroctocog alfa) LP-006034. [Electronic resource]: https://grls.rosminzdrav.ru/GRLS.aspx (appeal date 17.08.2020). (In Russ.)].

2. McCue J., Kshirsagar R., Selvitelli K., Lu Q., Zhang M., Mei B., Peters R., Pierce G.F., Dumont J., Raso S., Reichert H. Manufacturing process used to produce long-acting recombinant factor VIII Fc fusion protein. Biologicals 2015;43(4):213–9. doi: 10.1016/j.biologicals.2015.05.012.

3. Rath T., Baker K., Dumont J.A., Peters R.T., Jiang H., Qiao S.-W., Lencer W.I., Pierce G.F., Blumberg R.S. Fc-fusion proteins and FcRn: structural insights for longer-lasting and more effective therapeutics. Crit Rev Biotechnol 2015;35(2):235–54. doi: 10.3109/07388551.2013.834293.

4. Powell J.S., Josephson N.C., Quon D., Ragni M.V., Cheng G., Li E., Jiang H., Li L., Dumont J.A., Goyal J., Zhang X., Sommer J., McCue J., Barbetti M., Luk A., Pierce G.F. Safety and prolonged activity of recombinant factor VIII Fc fusion protein in haemophilia A patients. Blood 2012;119(13):3031–7. doi: 10.1182/blood-2011-09-382846.

5. Young G., Mahlangu J., Kulkarni R., Nolan B., Liesner R., Pasi J., Barnes C., Neelakantan S., Gambino G., Cristiano L.M., Pierce G.F., Allen G. Recombinant factor VIII Fc fusion protein for the prevention and treatment of bleeding in children with severe hemophilia A. J Thromb Haemost 2015;13(6):967–77. doi: 10.1111/jth.12911.

6. Nolan B., Mahlangu J., Pabinger I., Young G., Konkle B.A., Barnes C., Nogami K., Santagostino E., Pasi K.J., Khoo L., Winding B., Yuan H., Fruebis J., Rudin D., Oldenburg J. Recombinant factor VIII Fc fusion protein for the treatment of severe haemophilia A: Final results from the ASPIRE extension study. Haemophilia 2020;26(3):494–502. doi: 10.1111/hae.13953.

7. Scott M., Wall C., Xiang H. et al. Within-patient and matched-pair comparison of real-world outcomes in patients using rFVIII and rFVIIIFc prophylaxis, in the UK. Presented at EAHAD 2020. Poster 073.

8. Rayment R., Chalmers E., Forsyth K., Gooding R., Kelly A.M., Shapiro S., Talks K., Tunstall O., Biss T.; British Society for Haematology. Guidelines on the use of prophylactic factor replacement for children and adults with Haemophilia A and B. Br J Haematol 2020. doi: 10.1111/bjh.16704.

9. Srivastava A., Santagostino E., Dougall A., Kitchen S., Sutherland M., Pipe S.W., Carcao M., Mahlangu J., Ragni M.V., Windyga J., Llinás A., Goddard N.J., Mohan R., Poonnoose P.M., Feldman B.M., Lewis S.Z., van den Berg H.M., Pierce G.F.; WFH Guidelines for the Management of Hemophilia panelists and co-authors. WFH Guidelines for the Management of Hemophilia, 3rd edition. Haemophilia 2020. doi: 10.1111/hae.14046.